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Major hemorrhage is the most important complication of
vitamin K antagonists (VKAs) such as warfarin, acenocouma-
rol and phenprocoumon. This risk is substantial (1–3% per
year), even when the International Normalized Ratio (INR) is
in the therapeutic range [1]. Several genetic and acquired
patient characteristics such as advanced age, previous gastro-
intestinal bleeding, arterial hypertension, malignancy, and
cytochrome P450 CYP2C9 or VKORC1 DNA polymor-
phisms are considered risk factors for bleeding during VKA
treatment [1–3].
One obvious risk factor candidate for bleeding is ABO blood
group. ABOblood group is associatedwith the plasma levels of
von Willebrand factor (VWF), which in turn is the major
determinant of factor (F) VIII levels [4–6]; two crucial
procoagulant proteins that are not taken into account by the
INR. Therefore, we set out to establish the relationship
between ABO blood group genotypes and bleeding risk during
VKA treatment.
We used data from a case–control study (FACTORS:
FACTors in ORal anticoagulation Safety) that was designed
to search for risk factors for bleeding during anticoagulant
treatment with acenocoumarol or phenprocoumon [2,3].
Patients from two Dutch anticoagulation clinics, who had
experienced a non-traumatic non-fatal major bleeding compli-
cation during the period 1999–2001, were asked to partici-
pate in this study. Major bleeding was deﬁned as bleeding
leading to death or hospitalization, hemoglobin decrease
‡ 1.25 mmol L)1, intracranial, intraocular, muscle and joint
bleeding. The controls were selected from the same database,
considering age, indication of anticoagulation (e.g. atrial
ﬁbrillation, venous thromboembolism,mechanical heart valve),
sex, anticoagulation clinic, type of VKA (acenocoumarol or
phenprocoumon) and whether the drug had been discontinued
prior to time of blood collection.We enrolled 110 cases and 220
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controls. International Review Boards of Academic Medical
Center in Amsterdam and Leiden University Medical Center
approved the study and all participating subjects signed an
informed consent form before inclusion in the project.
Blood was collected in 3.2% sodium citrate solution and
kept at 4 C until centrifugation for 20 min at 2250 · g, 4 C.
Plasma was stored at )80 C and used to measure FVIII
activity (FVIII:C) and VWF antigen (VWF:Ag). FVIII:C was
measured with a one-stage clotting assay on a Behring
Coagulation System (Dade Behring, Marburg, Germany) with
protocols and reagents from the manufacturer. VWF:Ag levels
were determined with an in-house ELISA, using antibodies
fromDako (Glostrup, Denmark). FVIII activity and VWF:Ag
levels were determined relative to a plasma pool of > 170
healthy individuals that was calibrated against the 21st (NIBSC
00/586) and 9th British standard (NIBSC 01/168), respectively.
DNA, which was extracted from the remnant white blood
cells and stored at )20 C, was used for polymerase chain
reactions (PCR) in order to establish blood group. The PCR
protocols were designed to amplify exons 6 and 7 of the ABO
gene in two separated reactions. The sequence of the primers
was described previously by Olsson and Chester [7]. The PCR
products that correspond to exons 6 and 7 were digested with
the restriction enzymes KpnI and Msp, respectively (New
England BioLabs, Ipswich,MA,USA). The digestion products
were analyzed by electrophoresis using a 4%agarose gel. It was
possible to identify A1, A2, B, O1 and O2 alleles. The genetic
analysis of blood groups was conﬁrmed in 320 individuals by
serological test using a commercial kit (DiaCellA1,B; Dia-
Med, Cressier s/Morat, Switzerland).
The statistical analysis was performed in SPSS 12.0.1 (SPSS
Inc., Chicago, IL, USA). Odds ratios (OR) were calculated by
unconditional logistic regression, and 95% conﬁdence intervals
(95% CI) were based on the model.
The distribution of ABO blood groups in cases and controls
is listed in Table 1. In total, fourteen different ABO genotypes
were observed. For simplicity, the ABO genotypes were also
categorized in anOO blood group (O1O1/O1O2) and a non-OO
blood group (the other genotypes).
Odds ratio and 95% CI are shown in Table 2. The bleeding
risk in non-OO blood group carriers was 30% lower than in
carriers of OO blood group (OR 0.7; 95% CI: 0.4–1.1). In the
extended analyses for each blood group, using the OO blood
group as the reference category, the groups that remained
protective against bleeding were A1A1, A1A2, BB, BO andA1O
combinations. The AB genotypes did not present a lower
bleeding risk, although the number of patients in this group
was very small. The A2A2 and A2O combinations did not differ
from OO genotype, which is in keeping with similar low
efﬁcacy of the enzymes that result fromA2 and O alleles [8–10].
This ﬁnding is also in agreement with the fact that A2A2 and
A2O combinations also did not modify thrombosis risk [4].
It is probable that ABO blood group acts as a risk factor for
bleeding bymodifying the levels of FVIII:C andVWF:Ag [5,6],
Table 1 The distribution of ABO blood group genotypes with the respective factor VIII activity (FVIII:C) and von willebrand factor antigen (VWF:Ag)
means ± SEM in cases and controls
Genotypes
Total (%)
n ¼ 330
Cases (%)
n ¼ 110
Cases
Controls (%)
n ¼ 220
Controls
FVIII mean
± SEM %
VWF mean
± SEM %
FVIII mean
± SEM %
VWF mean
± SEM %
O1O1/O1O2 128 (39) 50 (46) 114 ± 4 150 ± 8 78 (35) 107 ± 2 131 ± 5
Non-OO 192 (58) 59 (53) 126 ± 4* 191 ± 9* 133 (61) 122 ± 2 168 ± 4
A1A1/A1A2 19 (6) 4 (4) 136 ± 7* 237 ± 14* 15 (7) 118 ± 3 163 ± 10
A1O1/A1O2 92 (28) 28 (25) 126 ± 5 190 ± 12* 64 (29) 120 ± 3 166 ± 5
A2O1/A2O2/A2A2 38 (11) 15 (14) 118 ± 7 171 ± 21 23 (11) 116 ± 5 164 ± 18
BB/BO1/BO2 33 (10) 7 (6) 130 ± 19 189 ± 31 26 (12) 134 ± 6 175 ± 8
A1B/A2B 10 (3) 5 (4) 132 ± 11 219 ± 28* 5 (2) 127 ± 8 177 ± 22
Missing samples 10 (3) 1 (1) 9 (4)
*Statistically signiﬁcant diﬀerence comparing with the OO blood group in cases.
Statistically signiﬁcant diﬀerence comparing with the OO blood group in controls.
Table 2 The bleeding risk for ABO blood group genotypes
Analysed groups
OR
(95% CI)
Adjusted OR
for FVIII
(95% CI)
Adjusted OR
for VWF
(95% CI)
Adjusted OR
for FVIII/VWF
(95% CI)
OO 1 1 1 1
Non-OO 0.7 (0.4–1.1) 0.6 (0.4–1.0) 0.5 (0.3–0.9) 0.5 (0.3–0.8)
A1A1/A1A2 0.4 (0.1–1.3) 0.3 (0.1–1.1) 0.3 (0.1–0.9) 0.3 (0.1–0.9)
A1O1/A1O2 0.7 (0.4–1.2) 0.7 (0.5–1.0) 0.7 (0.5–1.0) 0.7 (0.5–0.9)
A2O1/A2O2/A2A2 1.0 (0.5–2.1) 1.0 (0.7–1.2) 0.9 (0.7–1.2) 0.9 (0.7–1.2)
BB/BO1/BO2 0.4 (0.2–1.0) 0.8 (0.6–1.0) 0.7 (0.6–0.9) 0.7 (0.6–1.0)
A1B/A2B 1.6 (0.4–5.7) 1.0 (0.8–1.3) 1.0 (0.7–1.3) 1.0 (0.7–1.3)
FVIII, factor VIII; OR, odds ratio; VWF, von Willebrand factor.
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and therefore these levels were measured. As expected, the
means of FVIII:C in the controls were lower (107%) for OO
blood group carriers than for non-OO blood group carriers
(122%, P < 0.0001). Similarly, VWF:Ag levels were 131% in
OO individuals and 168% in non-OO individuals
(P < 0.0001). When categorized according to blood group,
levels of FVIII:C were 114% for OO blood group and 126%
for non-OO blood group (P ¼ 0.035), while levels of VWF:Ag
were 150% and 190% (P ¼ 0.002), respectively (Table 1). We
interpret these data as indicating that blood group-mediated
increases in the levels of FVIII:C and VWF:Ag, as observed in
non-OO carriers, protect against bleeding. Such a conclusion is
indirectly supported by the opposite ﬁndings in venous
thrombosis, where non-OO blood group seems to increase
the risk of a thrombotic event [4].
We then evaluated whether the bleeding risks were affected
by adjustment for FVIII:C levels or VWF:Ag levels. The
bleeding risk for non-OO carriers compared with OO carriers
decreased somewhat further after adjustment for FVIII:C only
(OR 0.6; 95% CI: 0.4–1.0), for VWF:Ag only (OR 0.5; 95%
CI: 0.3–0.9) and for both FVIII:C and VWF:Ag (OR 0.5; 95%
CI: 0.3–0.8).
One possible explanation for this effect of adjustment for
FVIII:C levels and VWF:Ag levels is the ﬁnding that,
paradoxically, FVIII:C and VWF:Ag levels (irrespective of
blood group) were higher in cases than in controls. In isolation,
this ﬁnding would suggest that higher levels of FVIII:C and
VWF:Ag increase the risk for bleeding under VKA therapy,
which is opposite to the conclusion based on the blood group
analysis. This ﬁnding suggested that another causal pathway,
possibly involving endothelial damage, increased both levels of
FVIII:C and VWF:Ag and bleeding risk during VKA treat-
ment. Such a scenario ﬁnds support in the notion that both
FVIII and VWF are known to respond to endothelial
activation and their high levels can be maintained if the
stimulation continues, like vascular inﬂammation [11].
In conclusion, this study suggests a decreased bleeding risk in
non-OO genotype carriers during treatment with acenocouma-
rol and phenprocoumon, and the way that FVIII and VWF
levels decrease this risk needs to be elucidated.
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